Clinical trial · Observational
A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Therapeutic targeting of immune checkpoints PD-1/PD-L1 and/or CTLA-4 is efficient in several solid cancer subtypes, however only some patients do experience clinical benefit from these treatments. One explanation could be that multiple redundant checkpoints are present within the tumor, simultaneously keeping in check the patient's immune response. The immune checkpoint HLA-G is neo-expressed in over 50% of cases in some cancer subtypes and associated with more dismal prognosis. The immunosuppressive effects of HLA-G may result in resistance to current immunotherapy drugs. The GEIA study explores the impact of HLA-G tumor expression on the efficacy of cancer immunotherapy in solid cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients with advanced solid cancer treated with anti-PD(L)1
- description
- Adult patients with advanced solid cancer treated with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy.
Primary outcomes (1)
- measure
- Objective tumor response rate
- timeFrame
- at 6 months
- description
- The impact of HLA-G tumor expression (evaluated by immunohistochemistry) on tumor response rates (evaluated with iRECIST) in solid cancer patients treated with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy.
Secondary outcomes (11)
- measure
- Progression free-survival
- timeFrame
- at 6 months
- measure
- Progression free-survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 or older * Social insurance * Ability to provide signed consent * Histologically proven solid cancer (non-small cell lung cancer, urothelial carcinoma, renal cell carcinoma, other) * Advanced and/or metastatic disease not accessible to local treatment * At least one target lesion according to iRECIST * Available fixed tumor sample for immunohistochemistry studies * Treatment with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy Exclusion Criteria: * Women pregnant or breastfeeding * Inability to consent to this research * Previous cancer immunotherapy (except BCG instillations for non-muscle infiltrative bladder cancer) * Patients chronically infected with HIV, HBV or HCV
References
Publications (0)
Data not yet available